Irinotecan 40mg
| Product Overview | |
| Generic Name | Irinotecan 40mg | 
| Brand Name(s) | Campto® (Pfizer), Irinotel® | 
| Form | Inj Vial | 
| Strength | 40 mg | 
| Therapeutic Class | Topoisomerase I inhibitor | 
| ATC Code | L01XX19 | 
| Manufacturing & Regulatory | |
| Manufacturer | Multiple Firms | 
| Country | India | 
| GMP Compliance | WHO-GMP certified facility | 
| DMF/CEP | Unknown – request from mfg | 
| COFEPRIS | Registered – exact Clave pending | 
| Free Sale Certificate | Yes | 
| Logistics & Export | |
| MOQ | 10 vials | 
| Shelf Life | 12-24 Months | 
| Storage | 2–8 °C, cool & dry | 
| Incoterms | Exworks, DDP, FOB | 
| Lead Time | 2 weeks | 
| Documentation | |
| Certificate of Analysis (COA) | Manufacturer provides COA | 
| SDS | Available on request | 
| CTD Summary | Available upon purchase with fee | 
Description
Indications & Usage: Antineoplastic agent in FOLFIRI regimens for metastatic colorectal cancer; causes diarrhea and neutropenia; blocks topoisomerase I preventing DNA replication. Used in FOLFIRI, second-line colorectal, other GI tumors; diarrhoea and myelosuppression risk.
 
				